Haloperidol LAI Dosing Conversion from Oral
For a patient stable on 15 mg oral haloperidol daily, initiate haloperidol decanoate at 150-300 mg intramuscularly every 4 weeks, using 10-20 times the daily oral dose as recommended by the FDA label. 1
Recommended Conversion Algorithm
The FDA-approved conversion is straightforward:
- Calculate: 15 mg oral daily × 10-20 = 150-300 mg IM every 4 weeks
- Start conservatively: Use 150 mg (10× conversion) initially for most patients
- Consider 225 mg (15× conversion) for patients with severe symptoms or prior stability issues
- Reserve 300 mg (20× conversion) only for severely disturbed or treatment-resistant patients
Evidence Supporting This Approach
The FDA label explicitly states that "for an initial approximation of the total daily dose required, the parenteral dose administered in the preceding 24 hours may be used" and recommends multiplying the oral daily dose by 10-20 times for monthly depot administration 1. This is not arbitrary—multiple clinical trials validate this range:
The 10-20× conversion maintains therapeutic efficacy: A 1986 trial demonstrated that haloperidol decanoate at 9.4-15 times the oral dose provided equivalent symptom control with sustained plasma levels throughout the 4-week interval 2
The 20× factor is most commonly studied: A 1980 multicenter study found the 20-fold schedule adequate for most chronic psychotic patients, with stable plasma levels approximately 2 times higher than oral treatment 3
Lower conversions (10-15×) are increasingly preferred: Recent 2024 data shows that 41.5% of clinicians use doses below the 10× conversion, suggesting a trend toward more conservative dosing 4
Practical Considerations
For your patient on 15 mg oral:
- First-line choice: 150 mg IM monthly (10× conversion)—this is the lower end but provides adequate coverage based on pharmacokinetic data showing sustained release 2
- If inadequate response after 2 months: Increase to 225 mg monthly
- Maximum consideration: 300 mg monthly only if severely symptomatic
Timing of conversion: Administer the first decanoate injection within 12-24 hours of the last oral dose, then continue oral haloperidol for 3-5 days during the overlap period to prevent symptom breakthrough 1.
Common Pitfalls to Avoid
- Don't automatically use 20× conversion: While historically common 3, 5, this may be excessive for stable patients and increases extrapyramidal symptom risk
- Don't forget the overlap period: Abrupt discontinuation of oral haloperidol can cause symptom exacerbation before depot reaches steady state (typically after the second injection) 3
- Don't ignore metabolizer status: CYP2D6 poor metabolizers may need lower doses, while ultra-rapid metabolizers may need higher doses 6
The 10-20× conversion range is well-established and safe, with no increased adverse events compared to oral formulations 2, 3. For 15 mg oral daily, start with 150 mg IM monthly and titrate upward only if clinically necessary.